A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-05-06

AUTHORS

Jacqueline Brown, Savannah Scardo, Michael Method, Dan Schlauch, Amanda Misch, Shaita Picard, Erika Hamilton, Suzanne Jones, Howard Burris, David Spigel

ABSTRACT

BackgroundThe National Comprehensive Cancer Network recommends that patients with hormone receptor-positive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision. Adjuvant chemotherapy (CT) use primarily depends on risk of recurrence. Biomarkers such as Ki-67 potentially have most value in patients with intermediate risk factors, such as involvement of 1–3 positive nodes. This study evaluated the use of Ki-67 testing and treatment patterns in patients with HR+, human epidermal growth factor receptor 2-negative early breast cancer.MethodsThis was an observational retrospective cohort study of patients with electronic medical records from January 2010 to August 2018 treated for HR+, HER2− early breast cancer at Sarah Cannon sites in the United States (US). Overall, 567 patients were randomly selected after using the eligibility criteria: female or male ≥18 years, without distant metastases, and with available physician and pathology reports. Multivariable logistic regression was used to investigate factors predicting Ki-67 testing and test results. Descriptive analyses were applied to treatment patterns.ResultsMultivariable logistic regression analyses found no clinical or pathological factors that predicted whether Ki-67 testing had been ordered by physicians. Of all tested patients (N = 130), having Grade-2 tumors (OR, 7.95 [95% CI: 2.05, 30.9]; p = 0.0027) or Grade-3 tumors (OR, 95.3 [95% CI, 11.9, 760.7]; p < 0.001) at initial diagnosis was a predictor of high Ki-67 expression (≥20%). Ki-67 expression was tested in 23.6% (61/258) of patients with 1–3 positive nodes; 54.1% of them (33/61) had high Ki-67 expression (≥20%). While having a higher grade tumor predicted high Ki-67 (≥20%), 28.6% of patients with Grade-1 tumors also had high Ki-67 expression. Neo-adjuvant therapy was received by 16.0% of patients (91/567), most of whom (66/91; 72.5%) received CT alone. Adjuvant therapy, either endocrine and/or chemotherapy, was received by 92.6% (525/567) of patients and by 67.0% (61/91) of those who received neo-adjuvant therapy. Most (428/525, 81.5%) received ET in the adjuvant treatment setting.ConclusionsHigh grade tumors predicted high Ki-67 (≥20%) expression, but Ki-67 testing was not widely used in these US patients. Most HR+, HER2− early breast cancers were treated with adjuvant ET, with or without CT. More... »

PAGES

502

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6

DOI

http://dx.doi.org/10.1186/s12885-022-09557-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147688001

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35524219


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ki-67 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, ErbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU, Bracknell, UK", 
          "id": "http://www.grid.ac/institutes/grid.418786.4", 
          "name": [
            "Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU, Bracknell, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brown", 
        "givenName": "Jacqueline", 
        "id": "sg:person.014456706621.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014456706621.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scardo", 
        "givenName": "Savannah", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly and Company, Indianapolis, IN, USA", 
          "id": "http://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Eli Lilly and Company, Indianapolis, IN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Method", 
        "givenName": "Michael", 
        "id": "sg:person.07352437521.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07352437521.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genospace, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Genospace, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schlauch", 
        "givenName": "Dan", 
        "id": "sg:person.010621214353.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010621214353.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genospace, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Genospace, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Misch", 
        "givenName": "Amanda", 
        "id": "sg:person.015646564331.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015646564331.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genospace, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Genospace, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Picard", 
        "givenName": "Shaita", 
        "id": "sg:person.014253623331.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014253623331.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tennessee Oncology, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.492963.3", 
          "name": [
            "Sarah Cannon, Nashville, TN, USA", 
            "Tennessee Oncology, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamilton", 
        "givenName": "Erika", 
        "id": "sg:person.01315576133.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315576133.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sarah Cannon, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.419513.b", 
          "name": [
            "Sarah Cannon, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "Suzanne", 
        "id": "sg:person.014751065647.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014751065647.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tennessee Oncology, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.492963.3", 
          "name": [
            "Sarah Cannon, Nashville, TN, USA", 
            "Tennessee Oncology, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burris", 
        "givenName": "Howard", 
        "id": "sg:person.01207006231.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207006231.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tennessee Oncology, Nashville, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.492963.3", 
          "name": [
            "Sarah Cannon, Nashville, TN, USA", 
            "Tennessee Oncology, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spigel", 
        "givenName": "David", 
        "id": "sg:person.01203145131.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203145131.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/bcr2607", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009736506", 
          "https://doi.org/10.1186/bcr2607"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-016-3950-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034857407", 
          "https://doi.org/10.1007/s10549-016-3950-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12916-015-0369-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003969537", 
          "https://doi.org/10.1186/s12916-015-0369-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41416-019-0656-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1122986074", 
          "https://doi.org/10.1038/s41416-019-0656-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-019-05198-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1112731714", 
          "https://doi.org/10.1007/s10549-019-05198-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-05-06", 
    "datePublishedReg": "2022-05-06", 
    "description": "BackgroundThe National Comprehensive Cancer Network recommends that patients with hormone receptor-positive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision. Adjuvant chemotherapy (CT) use primarily depends on risk of recurrence. Biomarkers such as Ki-67 potentially have most value in patients with intermediate risk factors, such as involvement of 1\u20133 positive nodes. This study evaluated the use of Ki-67 testing and treatment patterns in patients with HR+, human epidermal growth factor receptor 2-negative early breast cancer.MethodsThis was an observational retrospective cohort study of patients with electronic medical records from January 2010 to August 2018 treated for HR+, HER2\u2212 early breast cancer at Sarah Cannon sites in the United States (US). Overall, 567 patients were randomly selected after using the eligibility criteria: female or male \u226518\u2009years, without distant metastases, and with available physician and pathology reports. Multivariable logistic regression was used to investigate factors predicting Ki-67 testing and test results. Descriptive analyses were applied to treatment patterns.ResultsMultivariable logistic regression analyses found no clinical or pathological factors that predicted whether Ki-67 testing had been ordered by physicians. Of all tested patients (N\u2009=\u00a0130), having Grade-2 tumors (OR, 7.95 [95% CI: 2.05, 30.9]; p\u2009=\u20090.0027) or Grade-3 tumors (OR, 95.3 [95% CI, 11.9, 760.7]; p\u2009<\u20090.001) at initial diagnosis was a predictor of high Ki-67 expression (\u226520%). Ki-67 expression was tested in 23.6% (61/258) of patients with 1\u20133 positive nodes; 54.1% of them (33/61) had high Ki-67 expression (\u226520%). While having a higher grade tumor predicted high Ki-67 (\u226520%), 28.6% of patients with Grade-1 tumors also had high Ki-67 expression. Neo-adjuvant therapy was received by 16.0% of patients (91/567), most of whom (66/91; 72.5%) received CT alone. Adjuvant therapy, either endocrine and/or chemotherapy, was received by 92.6% (525/567) of patients and by 67.0% (61/91) of those who received neo-adjuvant therapy. Most (428/525, 81.5%) received ET in the adjuvant treatment setting.ConclusionsHigh grade tumors predicted high Ki-67 (\u226520%) expression, but Ki-67 testing was not widely used in these US patients. Most HR+, HER2\u2212 early breast cancers were treated with adjuvant ET, with or without CT.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-022-09557-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "high Ki-67 expression", 
      "early breast cancer", 
      "Ki-67 expression", 
      "adjuvant endocrine therapy", 
      "neo-adjuvant therapy", 
      "endocrine therapy", 
      "breast cancer", 
      "treatment patterns", 
      "positive nodes", 
      "grade tumors", 
      "Ki-67", 
      "hormone receptor-positive early breast cancer", 
      "receptor-positive early breast cancer", 
      "observational retrospective cohort study", 
      "National Comprehensive Cancer Network", 
      "real-world retrospective study", 
      "human epidermal growth factor receptor", 
      "adjuvant treatment setting", 
      "retrospective cohort study", 
      "grade 3 tumors", 
      "Comprehensive Cancer Network", 
      "grade 1 tumors", 
      "risk of recurrence", 
      "intermediate risk factors", 
      "multivariable logistic regression", 
      "grade 2 tumors", 
      "high Ki-67", 
      "high-grade tumors", 
      "ResultsMultivariable logistic regression analysis", 
      "logistic regression analysis", 
      "electronic medical records", 
      "epidermal growth factor receptor", 
      "adjuvant chemotherapy", 
      "growth factor receptor", 
      "adjuvant therapy", 
      "cohort study", 
      "surgical excision", 
      "distant metastasis", 
      "initial diagnosis", 
      "US patients", 
      "retrospective study", 
      "risk factors", 
      "medical records", 
      "primary treatment", 
      "pathology reports", 
      "pathological factors", 
      "patients", 
      "eligibility criteria", 
      "Cancer Network", 
      "chemotherapy", 
      "available physicians", 
      "treatment settings", 
      "tumors", 
      "therapy", 
      "cancer", 
      "logistic regression", 
      "factor receptor", 
      "regression analysis", 
      "United States", 
      "physicians", 
      "expression", 
      "descriptive analysis", 
      "MethodsThis", 
      "recurrence", 
      "testing", 
      "metastasis", 
      "excision", 
      "factors", 
      "diagnosis", 
      "biomarkers", 
      "receptors", 
      "study", 
      "endocrine", 
      "treatment", 
      "risk", 
      "predictors", 
      "involvement", 
      "report", 
      "regression", 
      "patterns", 
      "years", 
      "setting", 
      "use", 
      "records", 
      "criteria", 
      "test results", 
      "nodes", 
      "analysis", 
      "most value", 
      "sites", 
      "results", 
      "values", 
      "state", 
      "network"
    ], 
    "name": "A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2\u2212 early breast cancer in the United States", 
    "pagination": "502", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147688001"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-022-09557-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35524219"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-022-09557-6", 
      "https://app.dimensions.ai/details/publication/pub.1147688001"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_929.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-022-09557-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-022-09557-6'


 

This table displays all metadata directly associated to this object as RDF triples.

294 TRIPLES      22 PREDICATES      136 URIs      123 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-022-09557-6 schema:about N0be95dda57a54affa9df48f73691ad2b
2 N115d7af938ae46d78e91d99d9ee5cf82
3 N125417461f06469c9ef6eaac55823f84
4 N16ae74c6298c450484368a288cea7f03
5 N5585f9550f264537adbc372b5ab59468
6 N8e36ac74b4d14f3e90a40466cdfffb71
7 Nb2b5a5fd93da4b8c9d23f4a9c8bc8c8e
8 Nba732e853a5e43b88ae83df95c06f26d
9 Nbbbf22919a2f4173a8555446cb53a919
10 Neaa80a2c36d64fdcb0779b6724944e08
11 Nfaca28b09153407b92393c8dad7331ee
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author Nbf81a52230384df088404e292204b5b7
15 schema:citation sg:pub.10.1007/s10549-016-3950-5
16 sg:pub.10.1007/s10549-019-05198-9
17 sg:pub.10.1038/s41416-019-0656-6
18 sg:pub.10.1186/bcr2607
19 sg:pub.10.1186/s12916-015-0369-5
20 schema:datePublished 2022-05-06
21 schema:datePublishedReg 2022-05-06
22 schema:description BackgroundThe National Comprehensive Cancer Network recommends that patients with hormone receptor-positive early breast cancer be considered for adjuvant endocrine therapy (ET) after primary treatment like surgical excision. Adjuvant chemotherapy (CT) use primarily depends on risk of recurrence. Biomarkers such as Ki-67 potentially have most value in patients with intermediate risk factors, such as involvement of 1–3 positive nodes. This study evaluated the use of Ki-67 testing and treatment patterns in patients with HR+, human epidermal growth factor receptor 2-negative early breast cancer.MethodsThis was an observational retrospective cohort study of patients with electronic medical records from January 2010 to August 2018 treated for HR+, HER2− early breast cancer at Sarah Cannon sites in the United States (US). Overall, 567 patients were randomly selected after using the eligibility criteria: female or male ≥18 years, without distant metastases, and with available physician and pathology reports. Multivariable logistic regression was used to investigate factors predicting Ki-67 testing and test results. Descriptive analyses were applied to treatment patterns.ResultsMultivariable logistic regression analyses found no clinical or pathological factors that predicted whether Ki-67 testing had been ordered by physicians. Of all tested patients (N = 130), having Grade-2 tumors (OR, 7.95 [95% CI: 2.05, 30.9]; p = 0.0027) or Grade-3 tumors (OR, 95.3 [95% CI, 11.9, 760.7]; p < 0.001) at initial diagnosis was a predictor of high Ki-67 expression (≥20%). Ki-67 expression was tested in 23.6% (61/258) of patients with 1–3 positive nodes; 54.1% of them (33/61) had high Ki-67 expression (≥20%). While having a higher grade tumor predicted high Ki-67 (≥20%), 28.6% of patients with Grade-1 tumors also had high Ki-67 expression. Neo-adjuvant therapy was received by 16.0% of patients (91/567), most of whom (66/91; 72.5%) received CT alone. Adjuvant therapy, either endocrine and/or chemotherapy, was received by 92.6% (525/567) of patients and by 67.0% (61/91) of those who received neo-adjuvant therapy. Most (428/525, 81.5%) received ET in the adjuvant treatment setting.ConclusionsHigh grade tumors predicted high Ki-67 (≥20%) expression, but Ki-67 testing was not widely used in these US patients. Most HR+, HER2− early breast cancers were treated with adjuvant ET, with or without CT.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N2386841900464968810b6b4128fc4095
27 Nf1e251a607c241cd868414c32ac881c6
28 sg:journal.1024632
29 schema:keywords Cancer Network
30 Comprehensive Cancer Network
31 Ki-67
32 Ki-67 expression
33 MethodsThis
34 National Comprehensive Cancer Network
35 ResultsMultivariable logistic regression analysis
36 US patients
37 United States
38 adjuvant chemotherapy
39 adjuvant endocrine therapy
40 adjuvant therapy
41 adjuvant treatment setting
42 analysis
43 available physicians
44 biomarkers
45 breast cancer
46 cancer
47 chemotherapy
48 cohort study
49 criteria
50 descriptive analysis
51 diagnosis
52 distant metastasis
53 early breast cancer
54 electronic medical records
55 eligibility criteria
56 endocrine
57 endocrine therapy
58 epidermal growth factor receptor
59 excision
60 expression
61 factor receptor
62 factors
63 grade 1 tumors
64 grade 2 tumors
65 grade 3 tumors
66 grade tumors
67 growth factor receptor
68 high Ki-67
69 high Ki-67 expression
70 high-grade tumors
71 hormone receptor-positive early breast cancer
72 human epidermal growth factor receptor
73 initial diagnosis
74 intermediate risk factors
75 involvement
76 logistic regression
77 logistic regression analysis
78 medical records
79 metastasis
80 most value
81 multivariable logistic regression
82 neo-adjuvant therapy
83 network
84 nodes
85 observational retrospective cohort study
86 pathological factors
87 pathology reports
88 patients
89 patterns
90 physicians
91 positive nodes
92 predictors
93 primary treatment
94 real-world retrospective study
95 receptor-positive early breast cancer
96 receptors
97 records
98 recurrence
99 regression
100 regression analysis
101 report
102 results
103 retrospective cohort study
104 retrospective study
105 risk
106 risk factors
107 risk of recurrence
108 setting
109 sites
110 state
111 study
112 surgical excision
113 test results
114 testing
115 therapy
116 treatment
117 treatment patterns
118 treatment settings
119 tumors
120 use
121 values
122 years
123 schema:name A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States
124 schema:pagination 502
125 schema:productId N48616dc8564544eeab8c419e35105cc4
126 Naff62fccd1d94769b0f86a0134a55bb6
127 Nd5515a2f362e408ea4c775d328e52c20
128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147688001
129 https://doi.org/10.1186/s12885-022-09557-6
130 schema:sdDatePublished 2022-06-01T22:25
131 schema:sdLicense https://scigraph.springernature.com/explorer/license/
132 schema:sdPublisher Nfa579881fc6245f3a9f23abfe62ea47a
133 schema:url https://doi.org/10.1186/s12885-022-09557-6
134 sgo:license sg:explorer/license/
135 sgo:sdDataset articles
136 rdf:type schema:ScholarlyArticle
137 N0be95dda57a54affa9df48f73691ad2b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Chemotherapy, Adjuvant
139 rdf:type schema:DefinedTerm
140 N115d7af938ae46d78e91d99d9ee5cf82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Retrospective Studies
142 rdf:type schema:DefinedTerm
143 N125417461f06469c9ef6eaac55823f84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Biomarkers, Tumor
145 rdf:type schema:DefinedTerm
146 N14be61d370cd406c90a9d5a86f4c944b rdf:first sg:person.010621214353.66
147 rdf:rest N9c164fd4c42449b4ac23fb8e912555bf
148 N16ae74c6298c450484368a288cea7f03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Male
150 rdf:type schema:DefinedTerm
151 N2386841900464968810b6b4128fc4095 schema:issueNumber 1
152 rdf:type schema:PublicationIssue
153 N287dacd028d24002a968d98548b4df03 rdf:first sg:person.01315576133.11
154 rdf:rest Nd78850b1eab8444bb7d485b682e38ab4
155 N48616dc8564544eeab8c419e35105cc4 schema:name dimensions_id
156 schema:value pub.1147688001
157 rdf:type schema:PropertyValue
158 N5585f9550f264537adbc372b5ab59468 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Breast Neoplasms
160 rdf:type schema:DefinedTerm
161 N83e2a6c73d7844728ad72ad8fbebae0d rdf:first sg:person.07352437521.03
162 rdf:rest N14be61d370cd406c90a9d5a86f4c944b
163 N8e36ac74b4d14f3e90a40466cdfffb71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Receptor, ErbB-2
165 rdf:type schema:DefinedTerm
166 N99f1c18f3c8849fca405537a0620e77f rdf:first Ne0eb1ec17784412590890223191a2263
167 rdf:rest N83e2a6c73d7844728ad72ad8fbebae0d
168 N9c164fd4c42449b4ac23fb8e912555bf rdf:first sg:person.015646564331.17
169 rdf:rest Nd2d45c8e5c6b436a8de47fc6bd94179c
170 N9c6d56fa48b542c8a9e103fb93beafcb rdf:first sg:person.01203145131.14
171 rdf:rest rdf:nil
172 Naff62fccd1d94769b0f86a0134a55bb6 schema:name doi
173 schema:value 10.1186/s12885-022-09557-6
174 rdf:type schema:PropertyValue
175 Nb2b5a5fd93da4b8c9d23f4a9c8bc8c8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name United States
177 rdf:type schema:DefinedTerm
178 Nba732e853a5e43b88ae83df95c06f26d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Female
180 rdf:type schema:DefinedTerm
181 Nbbbf22919a2f4173a8555446cb53a919 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Ki-67 Antigen
183 rdf:type schema:DefinedTerm
184 Nbf81a52230384df088404e292204b5b7 rdf:first sg:person.014456706621.28
185 rdf:rest N99f1c18f3c8849fca405537a0620e77f
186 Nd2d45c8e5c6b436a8de47fc6bd94179c rdf:first sg:person.014253623331.40
187 rdf:rest N287dacd028d24002a968d98548b4df03
188 Nd5515a2f362e408ea4c775d328e52c20 schema:name pubmed_id
189 schema:value 35524219
190 rdf:type schema:PropertyValue
191 Nd78850b1eab8444bb7d485b682e38ab4 rdf:first sg:person.014751065647.13
192 rdf:rest Ndac49ab92a454c31b4d5e99b9d2dbe69
193 Ndac49ab92a454c31b4d5e99b9d2dbe69 rdf:first sg:person.01207006231.53
194 rdf:rest N9c6d56fa48b542c8a9e103fb93beafcb
195 Ne0eb1ec17784412590890223191a2263 schema:affiliation grid-institutes:grid.417540.3
196 schema:familyName Scardo
197 schema:givenName Savannah
198 rdf:type schema:Person
199 Neaa80a2c36d64fdcb0779b6724944e08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Humans
201 rdf:type schema:DefinedTerm
202 Nf1e251a607c241cd868414c32ac881c6 schema:volumeNumber 22
203 rdf:type schema:PublicationVolume
204 Nfa579881fc6245f3a9f23abfe62ea47a schema:name Springer Nature - SN SciGraph project
205 rdf:type schema:Organization
206 Nfaca28b09153407b92393c8dad7331ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Receptors, Progesterone
208 rdf:type schema:DefinedTerm
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
213 schema:name Oncology and Carcinogenesis
214 rdf:type schema:DefinedTerm
215 sg:journal.1024632 schema:issn 1471-2407
216 schema:name BMC Cancer
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.010621214353.66 schema:affiliation grid-institutes:None
220 schema:familyName Schlauch
221 schema:givenName Dan
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010621214353.66
223 rdf:type schema:Person
224 sg:person.01203145131.14 schema:affiliation grid-institutes:grid.492963.3
225 schema:familyName Spigel
226 schema:givenName David
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203145131.14
228 rdf:type schema:Person
229 sg:person.01207006231.53 schema:affiliation grid-institutes:grid.492963.3
230 schema:familyName Burris
231 schema:givenName Howard
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207006231.53
233 rdf:type schema:Person
234 sg:person.01315576133.11 schema:affiliation grid-institutes:grid.492963.3
235 schema:familyName Hamilton
236 schema:givenName Erika
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315576133.11
238 rdf:type schema:Person
239 sg:person.014253623331.40 schema:affiliation grid-institutes:None
240 schema:familyName Picard
241 schema:givenName Shaita
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014253623331.40
243 rdf:type schema:Person
244 sg:person.014456706621.28 schema:affiliation grid-institutes:grid.418786.4
245 schema:familyName Brown
246 schema:givenName Jacqueline
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014456706621.28
248 rdf:type schema:Person
249 sg:person.014751065647.13 schema:affiliation grid-institutes:grid.419513.b
250 schema:familyName Jones
251 schema:givenName Suzanne
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014751065647.13
253 rdf:type schema:Person
254 sg:person.015646564331.17 schema:affiliation grid-institutes:None
255 schema:familyName Misch
256 schema:givenName Amanda
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015646564331.17
258 rdf:type schema:Person
259 sg:person.07352437521.03 schema:affiliation grid-institutes:grid.417540.3
260 schema:familyName Method
261 schema:givenName Michael
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07352437521.03
263 rdf:type schema:Person
264 sg:pub.10.1007/s10549-016-3950-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034857407
265 https://doi.org/10.1007/s10549-016-3950-5
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/s10549-019-05198-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112731714
268 https://doi.org/10.1007/s10549-019-05198-9
269 rdf:type schema:CreativeWork
270 sg:pub.10.1038/s41416-019-0656-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122986074
271 https://doi.org/10.1038/s41416-019-0656-6
272 rdf:type schema:CreativeWork
273 sg:pub.10.1186/bcr2607 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009736506
274 https://doi.org/10.1186/bcr2607
275 rdf:type schema:CreativeWork
276 sg:pub.10.1186/s12916-015-0369-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003969537
277 https://doi.org/10.1186/s12916-015-0369-5
278 rdf:type schema:CreativeWork
279 grid-institutes:None schema:alternateName Genospace, Boston, MA, USA
280 schema:name Genospace, Boston, MA, USA
281 rdf:type schema:Organization
282 grid-institutes:grid.417540.3 schema:alternateName Eli Lilly and Company, Indianapolis, IN, USA
283 schema:name Eli Lilly and Company, Indianapolis, IN, USA
284 rdf:type schema:Organization
285 grid-institutes:grid.418786.4 schema:alternateName Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU, Bracknell, UK
286 schema:name Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU, Bracknell, UK
287 rdf:type schema:Organization
288 grid-institutes:grid.419513.b schema:alternateName Sarah Cannon, Nashville, TN, USA
289 schema:name Sarah Cannon, Nashville, TN, USA
290 rdf:type schema:Organization
291 grid-institutes:grid.492963.3 schema:alternateName Tennessee Oncology, Nashville, TN, USA
292 schema:name Sarah Cannon, Nashville, TN, USA
293 Tennessee Oncology, Nashville, TN, USA
294 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...